An evaluation of pharmacists expectations towards pharmacogenomics

Pharmacogenomics

Volumn 14, Issue 2, 2013, Pages 165-175

  De Denus, Simon ^a,b   Letarte, Nathalie ^a,c   Hurlimann, Thierry ^a   Lambert, Jean Philippe ^d   Lavoie, Annie ^a,e   Robb, Laura ^b   Sheehan, Nancy L ^a,f   Turgeon, Jacques ^a   Vadnais, Barbara ^a,g  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Bélanger Lambert and Riopel ^*  (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

clinical practice; confidentiality; education; personalized medicine; pharmacists; pharmacogenomics

Indexed keywords

ACCESS TO INFORMATION; ADULT; AGED; ARTICLE; CANADA; CLINICAL PRACTICE; CONTINUING EDUCATION; EXPECTATION; FEMALE; GENETIC SCREENING; HEALTH CARE SURVEY; HUMAN; INTEGRATION; INTERNET; MALE; MEDICAL EDUCATION; MEDICAL RESEARCH; PATIENT CARE; PATIENT COUNSELING; PHARMACIST; PHARMACOGENOMICS; PROFESSIONAL KNOWLEDGE; PROFESSIONAL PRACTICE; PROFESSIONAL STANDARD;

ATTITUDE OF HEALTH PERSONNEL; EDUCATION, PHARMACY; PHARMACISTS; PHARMACOGENETICS; PROFESSIONAL ROLE; QUEBEC; QUESTIONNAIRES;

EID: 84872511500     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.197     Document Type: Article

References (48)

1. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291(5507), 1304-1351 (2001). (Pubitemid 32173090)
2. Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007). (Pubitemid 47598626)
3. - 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061-1073 (2010).
4. Mallal S, Phillips E, Carosi G et al. HLA-B 5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008). (Pubitemid 351214284)
5. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
6. Scott SA, Sangkuhl K, Gardner EE et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90(2), 328-332 (2011).
7. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011).
8. Feero WG, Kuo GM, Jenkins JF, Rackover MA. Pharmacist education in the era of genomic medicine. J. Am. Pharm. Assoc. (2003), e113-e121 (2012).
9. Cavallari LH, Overholser BR, Andersen D et al. Recommended basic science foundation necessary to prepare pharmacists to manage personnalized pharmacotherapy. Pharmacotherapy 30, e228-e235 (2010).
10. Dion-Labrie M, Fortin MC, Hebert MJ, Doucet H. The use of personalized medicine for patient selection for renal transplantation: Physicians' views on the clinical and ethical implications. BMC Med. Ethics 11, 5 (2010).
11. Fargher EA, Eddy C, Newman W et al. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8(11), 1511-1519 (2007). (Pubitemid 350286396)
12. Voora D, Gage BF. Is primary care ready for pharmacogenetics? Pharmacogenomics 7(1), 1-3 (2006).
13. Rogausch A, Prause D, Schallenberg A, Brockmoller J, Himmel W. Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics 7(1), 49-59 (2006).
14. Finegold P, Mathieson K, Holmes L et al. Is the UK public ready for genetic medicine? Per. Med. 5, 65-76 (2008).
15. Roederer MW, Van Riper M, Valgus J, Knafl G, McLeod H. Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. Per. Med. 9(1), 19-27 (2011).
16. McCullough KB, Formea CM, Berg KD et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am. J. Pharm. Educ. 75(3), 51 (2011).
17. Bonter K, Desjardins C, Currier N, Pun J, Ashbury FD. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open 1(1), e000110 (2011).
18. Haddy CA, Ward HM, Angley MT, Mckinnon RA. Consumers' views of pharmacogenetics: a qualitative study. Res. Social Adm. Pharm. 6(3), 221-231 (2010).
19. Stanek EJ, Sanders CL, Taber KA et al. Adoption of pharmacogenomic testing by us physicians: Results of a nationwide survey. Clin. Pharm. Ther. 91(3), 450-458 (2012).
20. Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 12(3), 197-204 (2012).
21. Laegsgaard MM, Mors O. Psychiatric genetic testing: attitudes and intentions among future users and providers. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147(3), 375-384 (2008). (Pubitemid 351536804)
22. Nielsen LF, Moldrup C. The diffusion of innovation: factors influencing the uptake of pharmacogenetics. Community Genet. 10(4), 231-241 (2007). (Pubitemid 47482083)
23. Allegra CJ, Jessup JM, Somerfield MR et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009).
24. Guttmacher AE, Porteous ME, McInerney JD. Educating health-care professionals about genetics and genomics. Nat. Rev. Genet. 8(2), 151-157 (2007). (Pubitemid 46122843)
25. Gurwitz D, Weizman A, Rehavi M. Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol. Sci. 24(3), 122-125 (2003). (Pubitemid 36293777)
26. Murphy JE, Green JS, Adams LA, Squire RB, Kuo GM, McKay A. Pharmacogenomics in the curricula of colleges and schools of pharmacy in the united states. Am. J Pharm. Educ. 74(1), 7 (2010).
27. Green JS, O'Brien TJ, Chiappinelli VA, Harralson AF. Pharmacogenomics instruction in US and canadian medical schools: implications for personalized medicine. Pharmacogenomics 11(9), 1331-1340 (2010).
28. Dodson C, Van Riper M. Analysis of clinicians' attitudes towards pharmacogenomics. Per. Med. 8(5), 533-540 (2011).
29. Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics. Overcoming genetic exceptionalism. Lancet Oncol. 11(6), 507-509 (2010).
30. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther. 92(4), 467-475 (2012).
31. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 91(4), 734-738 (2012).
32. Relling MV, Gardner EE, Sandborn WJ et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011).
33. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89(3), 464-467 (2011).
34. Otlowski M, Taylor S, Bombard Y. Genetic discrimination: international perspectives. Annu. Rev. Genomics Hum. Genet. 13, 433-454 (2012).
35. Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the scandinavian simvastatin survival study. Circulation 101(12), 1366-1371 (2000). (Pubitemid 30169856)
36. Keene CD, Cudaback E, Li X, Montine KS, Montine TJ. Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. Curr. Opin. Neurobiol. 21(6), 920-928 (2011).
37. O'Donnell PH, Bush A, Spitz J et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92(4), 446-449 (2012).
38. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N. Engl. J. Med. 364(6), 524-534 (2011).
39. Resta RG. Defining and redefining the scope and goals of genetic counseling. Am. J. Med. Genet. C Semin. Med. Genet. 142C(4), 269-275 (2006). (Pubitemid 44747454)
40. Crews KR, Cross SJ, McCormick JN et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am. J. Health Syst. Pharm. 68(2), 143-150 (2011).
41. O'Connor SK, Ferreri SP, Michaels NM et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics 13(8), 955-962 (2012).
42. Nelen M, Veltman JA. Genome and exome sequencing in the clinic: unbiased genomic approaches with a high diagnostic yield. Pharmacogenomics 13(5), 511-514 (2012).
43. Roberts JD, Wells GA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (rapid gene): a prospective, randomised, proof-of-concept trial. Lancet 379(9827), 1705-1711 (2012).
44. Hicks JK, Crews KR, Hoffman JM et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin. Pharmacol. Ther. 92(5), 563-566 (2012).
45. Beaulieu M, De Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics 11(11), 1573-1590 (2010).
46. Survey Monkey. www.surveymonkey.com
47. Canadian Life and Health Insurance Association Ltd. CLHIA position statement of genetic testing. www.clhia.ca/domino/html/clhia/clhia-lp4w-lnd- webstation.nsf/resources/Guidelines/$file/Genetic-Testing-CLHIA-Industry- Position-2010.pdf
48. Ordre des pharmaciens du Québec. Rapport annuel 2011-2012. www.opq.org/cms/Media/1270-38-fr- CA-0-rapport-annuel-2011-12-opq.pdf